These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 6153251)

  • 1. Inhibition of intraocular proliferations with intravitreal corticosteroids.
    Tano Y; Sugita G; Abrams G; Machemer R
    Am J Ophthalmol; 1980 Jan; 89(1):131-6. PubMed ID: 6153251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticosteroid inhibition of intraocular proliferation after injury.
    Tano Y; Chandler DB; McCuen BW; Machemer R
    Am J Ophthalmol; 1981 Feb; 91(2):184-9. PubMed ID: 7468732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intraocular pressure change and anterior segment parameters after intravitreal bevacizumab injection - Cannula size matters.
    Hamidi NA; Güneş İB; Baykara M
    Saudi J Ophthalmol; 2020; 34(4):247-250. PubMed ID: 34527866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).
    Kuppermann BD; Zacharias LC; Kenney MC
    Trans Am Ophthalmol Soc; 2014 Jul; 112():116-41. PubMed ID: 25646032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.
    Vadlapudi AD; Patel A; Cholkar K; Mitra AK
    Recent Pat Biomed Eng; 2012 Apr; 5(1):83-101. PubMed ID: 25414810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion.
    Maturi RK; Chen V; Raghinaru D; Bleau L; Stewart MW
    Clin Ophthalmol; 2014; 8():1057-64. PubMed ID: 24940042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uniform suspension of the clustered triamcinolone acetonide particle.
    Sugimoto M; Kondo M; Horiguchi M
    J Ophthalmol; 2013; 2013():315658. PubMed ID: 23431418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid use for diabetic macular edema: old fad or new trend?
    Stewart MW
    Curr Diab Rep; 2012 Aug; 12(4):364-75. PubMed ID: 22581206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.
    Garweg JG; Wegmann-Burns M; Goldblum D
    Graefes Arch Clin Exp Ophthalmol; 2006 Mar; 244(3):382-9. PubMed ID: 16091952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.
    Jonas JB; Kreissig I; Degenring RF
    Br J Ophthalmol; 2004 Dec; 88(12):1557-62. PubMed ID: 15548812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.
    Ciardella AP; Klancnik J; Schiff W; Barile G; Langton K; Chang S
    Br J Ophthalmol; 2004 Sep; 88(9):1131-6. PubMed ID: 15317702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of intravitreally delivered etanercept.
    Fauser S; Kalbacher H; Alteheld N; Koizumi K; Krohne TU; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2004 Jul; 242(7):582-6. PubMed ID: 15029504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].
    Jonas JB; Kreissig I; Kamppeter B; Degenring RF
    Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro.
    Cai J; Wei R; Ma X; Zhu H; Li Y
    Int Ophthalmol; 2001; 24(4):225-31. PubMed ID: 12678400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal triamcinolone acetonide for exudative age related macular degeneration.
    Jonas JB; Kreissig I; Hugger P; Sauder G; Panda-Jonas S; Degenring R
    Br J Ophthalmol; 2003 Apr; 87(4):462-8. PubMed ID: 12642311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure after intravitreal injection of triamcinolone acetonide.
    Jonas JB; Kreissig I; Degenring R
    Br J Ophthalmol; 2003 Jan; 87(1):24-7. PubMed ID: 12488256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.
    Jonas JB; Hayler JK; Panda-Jonas S
    Br J Ophthalmol; 2000 Sep; 84(9):1064-7. PubMed ID: 10966969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permeability and diffusion in vitreous humor: implications for drug delivery.
    Xu J; Heys JJ; Barocas VH; Randolph TW
    Pharm Res; 2000 Jun; 17(6):664-9. PubMed ID: 10955838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR.
    Hegazy HM; Peyman GA; Liang C; Unal MH; Molinari LC; Kazi AA
    Int Ophthalmol; 1998-1999; 22(4):239-46. PubMed ID: 10674869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in sustained release drug delivery for the treatment of intraocular disease.
    Velez G; Whitcup SM
    Br J Ophthalmol; 1999 Nov; 83(11):1225-9. PubMed ID: 10535845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.